secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2022-02-03T23:59:59+00:00
Accession:  0001564590-22-003814
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax names Metzger CEO as Morrison moves to President, Head of R&D
--------------------------------------------------------------------

- Michael Metzger appointed CEO, effective immediately; previously President & COO.
- Briggs Morrison becomes President, Head of R&D; remains on board.
- Metzger base salary $640,000, target bonus 60% of base; Morrison base $637,500, bonus up to 50%.
- Transition aligns roles with expertise; Metzger to focus on strategic vision and commercial prep.
- Morrison to focus on advancing SNDX-5613 and axatilimab toward NDA filings in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000156459022003814/0001564590-22-003814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000156459022003814/sndx-8k_20220202.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-003814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer